188 related articles for article (PubMed ID: 37038342)
1. Efficacy of transcatheter arterial chemoembolization combined with sirolimus for treating Kasabach-Merritt phenomenon in infants, a retrospective study.
Yin CG; Qi WW; Wang S; Pan D; Chen XL; Li SY
Ann Med; 2023 Dec; 55(1):2196090. PubMed ID: 37038342
[TBL] [Abstract][Full Text] [Related]
2. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
Wang Y; Kong L; Sun B; Cui J; Shen W
J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
5. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
6. Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options.
Schmid I; Klenk AK; Sparber-Sauer M; Koscielniak E; Maxwell R; Häberle B
World J Pediatr; 2018 Aug; 14(4):322-329. PubMed ID: 30054848
[TBL] [Abstract][Full Text] [Related]
7. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
[TBL] [Abstract][Full Text] [Related]
8. Rapidly enlarging "bruise" on the back of an infant. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt syndrome.
Chan S; Cassarino DS
JAMA Dermatol; 2013 Nov; 149(11):1337-8. PubMed ID: 24005816
[No Abstract] [Full Text] [Related]
9. Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants.
Harbers VEM; van der Salm N; Pegge SAH; van der Vleuten CJM; Verhoeven BH; Vrancken SLAG; Schultze Kool LJ; Fuijkschot J; Te Loo DMMWM
Br J Clin Pharmacol; 2022 Jun; 88(6):2769-2781. PubMed ID: 34957601
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.
Duan L; Renzi S; Weidman D; Waespe N; Chami R; Manson D; Cada M; Carcao M
J Pediatr Hematol Oncol; 2020 Jan; 42(1):74-78. PubMed ID: 30044355
[TBL] [Abstract][Full Text] [Related]
12. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
13. A case of sirolimus treatment of kaposiform hemangioendothelioma in the neck.
Kuwabara Y; Ozeki M; Hira K; Fujisaki H; Ohnishi H
Pediatr Int; 2022 Jan; 64(1):e15000. PubMed ID: 35289458
[No Abstract] [Full Text] [Related]
14. Cost and effectiveness comparison of sirolimus versus standard treatment in Kasabach-Merritt phenomenon: a real-world evidence study in Thailand.
Tongruang C; Wananukul S; Chatproedprai S; Narkbunnam N; Nitiyarom R; Sirachainan N; Natesirinilkul R; Chaweephisal P; Sosothikul D
Pediatr Hematol Oncol; 2024 Apr; 41(3):229-239. PubMed ID: 38235681
[TBL] [Abstract][Full Text] [Related]
15. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
16. A not so harmless mass: Kaposiform hemangioendothelioma complicated by a Kasabach-Merritt phenomenon.
Tribolet S; Hoyoux C; Boon LM; Cheruy C; Demarche M; Jamblin P; Roberti A; Willemaers V; Viellevoye R; Rigo V; Broux I
Arch Pediatr; 2019 Sep; 26(6):365-369. PubMed ID: 31353149
[TBL] [Abstract][Full Text] [Related]
17. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
Jahnel J; Lackner H; Reiterer F; Urlesberger B; Urban C
Klin Padiatr; 2012 Oct; 224(6):395-7. PubMed ID: 23070861
[No Abstract] [Full Text] [Related]
18. [Refractory kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: clinical analysis of 10 cases].
Zhang GL; Gao Y; Liu Y; Gu F; Su W; Qin Q; Chen JY; Zhang HH; Yang J; Liu XY
Zhonghua Er Ke Za Zhi; 2017 Sep; 55(9):700-704. PubMed ID: 28881518
[No Abstract] [Full Text] [Related]
19. Bone kaposiform hemangioendothelioma: A rare entity dramatically improved by sirolimus.
Boccara O; Dangien A; Fitoussi F; Ducou Le Pointe H; Coulomb L'Hermine A; Fraitag S; Lorrot M
J Paediatr Child Health; 2022 Sep; 58(9):1676-1679. PubMed ID: 35138010
[No Abstract] [Full Text] [Related]
20. Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon: a retrospective cohort study.
Zhang G; Chen H; Gao Y; Liu Y; Wang J; Liu XY
Br J Dermatol; 2018 May; 178(5):1213-1214. PubMed ID: 29388191
[No Abstract] [Full Text] [Related]
[Next] [New Search]